Search

Your search keyword '"Zhong, Hongzhen"' showing total 42 results
Start Over Author "Zhong, Hongzhen"
42 results on '"Zhong, Hongzhen"'

2. How to Identify Boundary Conditions with Contrasty Metric?

Author

Luo, Weilin, Wan, Hai, Song, Xiaotong, Yang, Binhao, Zhong, Hongzhen, and Chen, Yin

Subjects
Computer Science - Software Engineering
Abstract

The boundary conditions (BCs) have shown great potential in requirements engineering because a BC captures the particular combination of circumstances, i.e., divergence, in which the goals of the requirement cannot be satisfied as a whole. Existing researches have attempted to automatically identify lots of BCs. Unfortunately, a large number of identified BCs make assessing and resolving divergences expensive. Existing methods adopt a coarse-grained metric, generality, to filter out less general BCs. However, the results still retain a large number of redundant BCs since a general BC potentially captures redundant circumstances that do not lead to a divergence. Furthermore, the likelihood of BC can be misled by redundant BCs resulting in costly repeatedly assessing and resolving divergences. In this paper, we present a fine-grained metric to filter out the redundant BCs. We first introduce the concept of contrasty of BC. Intuitively, if two BCs are contrastive, they capture different divergences. We argue that a set of contrastive BCs should be recommended to engineers, rather than a set of general BCs that potentially only indicates the same divergence. Then we design a post-processing framework (PPAc) to produce a set of contrastive BCs after identifying BCs. Experimental results show that the contrasty metric dramatically reduces the number of BCs recommended to engineers. Results also demonstrate that lots of BCs identified by the state-of-the-art method are redundant in most cases. Besides, to improve efficiency, we propose a joint framework (JAc) to interleave assessing based on the contrasty metric with identifying BCs. The primary intuition behind JAc is that it considers the search bias toward contrastive BCs during identifying BCs, thereby pruning the BCs capturing the same divergence. Experiments confirm the improvements of JAc in identifying contrastive BCs., Comment: to be published in ICSE21

Published
2021

3. Structural Similarity of Boundary Conditions and an Efficient Local Search Algorithm for Goal Conflict Identification

Author

Zhong, Hongzhen, Wan, Hai, Luo, Weilin, Xiao, Zhanhao, Li, Jia, and Fang, Biqing

Subjects
Computer Science - Software Engineering, Computer Science - Artificial Intelligence, Computer Science - Logic in Computer Science
Abstract

In goal-oriented requirements engineering, goal conflict identification is of fundamental importance for requirements analysis. The task aims to find the feasible situations which make the goals diverge within the domain, called boundary conditions (BCs). However, the existing approaches for goal conflict identification fail to find sufficient BCs and general BCs which cover more combinations of circumstances. From the BCs found by these existing approaches, we have observed an interesting phenomenon that there are some pairs of BCs are similar in formula structure, which occurs frequently in the experimental cases. In other words, once a BC is found, a new BC may be discovered quickly by slightly changing the former. It inspires us to develop a local search algorithm named LOGION to find BCs, in which the structural similarity is captured by the neighborhood relation of formulae. Based on structural similarity, LOGION can find a lot of BCs in a short time. Moreover, due to the large number of BCs identified, it potentially selects more general BCs from them. By taking experiments on a set of cases, we show that LOGION effectively exploits the structural similarity of BCs. We also compare our algorithm against the two state-of-the-art approaches. The experimental results show that LOGION produces one order of magnitude more BCs than the state-of-the-art approaches and confirm that LOGION finds out more general BCs thanks to a large number of BCs.

Published
2021

4. CoAPI: An Efficient Two-Phase Algorithm Using Core-Guided Over-Approximate Cover for Prime Compilation of Non-Clausal Formulae

Author

Luo, Weilin, Wan, Hai, Zhong, Hongzhen, and Wei, Ou

Subjects
Computer Science - Artificial Intelligence, Computer Science - Logic in Computer Science
Abstract

Prime compilation, i.e., the generation of all prime implicates or implicants (primes for short) of formulae, is a prominent fundamental issue for AI. Recently, the prime compilation for non-clausal formulae has received great attention. The state-of-the-art approaches generate all primes along with a prime cover constructed by prime implicates using dual rail encoding. However, the dual rail encoding potentially expands search space. In addition, constructing a prime cover, which is necessary for their methods, is time-consuming. To address these issues, we propose a novel two-phase method -- CoAPI. The two phases are the key to construct a cover without using dual rail encoding. Specifically, given a non-clausal formula, we first propose a core-guided method to rewrite the non-clausal formula into a cover constructed by over-approximate implicates in the first phase. Then, we generate all the primes based on the cover in the second phase. In order to reduce the size of the cover, we provide a multi-order based shrinking method, with a good tradeoff between the small size and efficiency, to compress the size of cover considerably. The experimental results show that CoAPI outperforms state-of-the-art approaches. Particularly, for generating all prime implicates, CoAPI consumes about one order of magnitude less time.

Published
2019

5. Trilayer Moiré Superlattices of MoS2 as a Simulator for the Ionic Hubbard Model on Honeycomb Lattice.

Author

Zhong, Hongzhen, Su, Zhixin, and Kang, Jun

Subjects
*HUBBARD model, *HONEYCOMBS, *HONEYCOMB structures, *CONDENSED matter, *SUPERLATTICES, *VALENCE bands, *ELECTRIC fields
Abstract

Recent studies have revealed the potential of 2D moiré superlattices as a condensed matter quantum simulator. The realization of different lattice model Hamiltonians in moiré superlattices has become the focus of researches. Here, it shows that, compared to bilayer moiré superlattices where there is only one interface, the interference between moiré patterns at different interfaces in 2D multilayer structures allows the physical realization of more complicated lattice models. The concept is demonstrated by trilayer moiré superlattices (TMSLs) of MoS2, where it finds that isolated flat moiré bands appear near the valence band edge, and they can be described by the honeycomb lattice ionic Hubbard model. More importantly, the hopping strength, the on‐site Coulomb repulsion, and the staggered potential in the TMSLs are highly tunable through the control of the twist angle, the dielectric environment, and the perpendicular electric field. It is possible to achieve various transitions between distinct quantum phases in the TMSLs, spanning from weak to strong correlation regimes. Therefore, the proposed TMSLs can serve as a good platform to study the strong correlation physics in the honeycomb lattice ionic Hubbard model. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Matrine Suppresses the Migration and Invasion of NSCLC Cells by Inhibiting PAX2-Induced Epithelial-Mesenchymal Transition [Retraction]

Author

Yang,Jun, He,Du, Peng,Yan, Zhong,Hongzhen, Deng,Yuhong, Yu,Zhonghua, Guan,Chengnong, Zuo,Yufang, Xu,Zumin, Yang,Jun, He,Du, Peng,Yan, Zhong,Hongzhen, Deng,Yuhong, Yu,Zhonghua, Guan,Chengnong, Zuo,Yufang, and Xu,Zumin

Abstract

Yang J, He D, Peng Y, et al. OncoTargets and Therapy. 2017;10:5209–5217. The Editor and Publisher of OncoTargets and Therapy wish to retract the published article. Following the authors request to make corrections an investigation found several images within Figures 2 and 5 appeared to have been duplicated. Figure 2A, A549, Migration, (0mg/mL), appears to have been duplicated with the same images for Figure 2A, A549, Migration, (0.5mg/mL); Invasion (0mg/mL); Invasion, (0.5mg/mL) and Figure 2B, H1299, Invasion, (0mg/mL). Figure 2A, A549, Migration, (1mg/mL), appears to have been duplicated with the same images for Figure 2A, A549, Invasion, (1mg/mL) and Figure 2B, H1299, Migration, (1mg/mL). Figure 5C, A459, GAPDH, appears to have been duplicated with the same image for Figure 5D, H1299, GAPDH. The authors cooperated with the investigation and provided data associated with the study. However, despite the authors’ assistance, they were unable to provide a satisfactory explanation for how the images came to be duplicated, and the validity of the published work could not be verified. The decision was made to retract the article and the authors agreed with this. We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Published
2023

30. Clinical efficacy and safety of rituximab in lupus nephritis

Author

Zhong, Zhiqing, Li, Hongyan, Zhong, Hongzhen, and Zhou, Tianbiao

Subjects
lupus nephritis, safety, meta-analysis, rituximab, Drug Design, Development and Therapy, systemic lupus erythematosus, Meta-Analysis as Topic, efficacy, Humans, Immunosuppressive Agents, Tacrolimus, Original Research
Abstract

Zhiqing Zhong,1,* Hongyan Li,2,* Hongzhen Zhong,1 Tianbiao Zhou1 1Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China; 2Department of Nephrology, Huadu District People’s Hospital of Guangzhou, Southern Medical University, 510800 Guangzhou, China *These authors contributed equally to this work Background: Long-term treatment programs with low toxicity represent a therapeutic challenge in lupus nephritis (LN). Although a therapeutic benefit of rituximab (RTX) has been reported in LN patients who have failed conventional treatment, the results are controversial. We aimed to assess the clinical efficacy and safety of RTX as a new immunosuppressive medicine in the treatment of LN with a meta-analysis. Methods: Based on predetermined criteria, PubMed, Embase, and Cochrane Library were used to identify the eligible studies. Cochrane Review Manager version 5.3 was applied to pool the data extracted from individual investigations and provide summary effect estimates. Results: Twenty-four studies with 940 patients were analyzed. In case series trials with specific LN assessment, the complete remission (CR) rate at 12 months was 35.9% (95% CI: 24.2%–49.5%), and total remission (TR: CR plus partial remission) was 73.4% (95% CI: 66.0%–79.7%). In controlled trials, RTX was associated with a higher probability of TR (OR =2.02, 95% CI: 1.23–3.32, P0.05). Additionally, RTX treatment significantly decreased proteinuria (mean difference: -2.79, 95% CI: -3.95 to -1.62, P

Published
2019

31. Clinical efficacy and safety of rituximab in lupus nephritis

Author

Zhong,Zhiqing, Li,Hongyan, Zhong,Hongzhen, Zhou,Tianbiao, Zhong,Zhiqing, Li,Hongyan, Zhong,Hongzhen, and Zhou,Tianbiao

Abstract

Zhiqing Zhong,1,* Hongyan Li,2,* Hongzhen Zhong,1 Tianbiao Zhou1 1Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, 515041 Shantou, China; 2Department of Nephrology, Huadu District People’s Hospital of Guangzhou, Southern Medical University, 510800 Guangzhou, China *These authors contributed equally to this work Background: Long-term treatment programs with low toxicity represent a therapeutic challenge in lupus nephritis (LN). Although a therapeutic benefit of rituximab (RTX) has been reported in LN patients who have failed conventional treatment, the results are controversial. We aimed to assess the clinical efficacy and safety of RTX as a new immunosuppressive medicine in the treatment of LN with a meta-analysis. Methods: Based on predetermined criteria, PubMed, Embase, and Cochrane Library were used to identify the eligible studies. Cochrane Review Manager version 5.3 was applied to pool the data extracted from individual investigations and provide summary effect estimates. Results: Twenty-four studies with 940 patients were analyzed. In case series trials with specific LN assessment, the complete remission (CR) rate at 12 months was 35.9% (95% CI: 24.2%–49.5%), and total remission (TR: CR plus partial remission) was 73.4% (95% CI: 66.0%–79.7%). In controlled trials, RTX was associated with a higher probability of TR (OR =2.02, 95% CI: 1.23–3.32, P<0.01). The CR in the RTX group was higher than that in the control group, although there was no significant difference between the two groups (OR =1.98, 95% CI: 0.90–4.39, P>0.05). Additionally, RTX treatment significantly decreased proteinuria (mean difference: -2.79, 95% CI: -3.95 to -1.62, P<0.01) as well as the renal activity index in patients with LN (mean difference: -3.46, 95% CI: -4.43 to -2.50, P<0.01). In controlled trials, the relative risks of the adverse events of infection and infusio

Published
2019

35. The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease

Author

zhong,Hongzhen, Zhou,Tianbiao, Li,Hongyan, Zhong,Zhiqing, zhong,Hongzhen, Zhou,Tianbiao, Li,Hongyan, and Zhong,Zhiqing

Abstract

Hongzhen Zhong,1,* Tianbiao Zhou,1,* Hongyan Li,2,* Zhiqing Zhong1,* 1Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, Shantou, China; 2Department of Nephrology, Huadu District People’s Hospital of Guangzhou, Southern Medical University, Guangzhou, China *These authors contributed equally to this work Introduction: The purpose of this study was to analyze the effects of hypoxia-inducible factor (HIF) stabilizers on anemia in non-dialysis-dependent (NDD) and dialysis-dependent (DD) chronic kidney disease (CKD) patients.Methods: Published studies were extracted from PubMed, China Biological Medicine Database (CBM), Wanfang database, and Cochrane Library on March 10, 2018, and relevant studies were pooled and included in a meta-analysis. Data on hemoglobin (Hb), ferritin, and hepcidin levels, total iron-binding capacity (TIBC), and incidence of adverse events (AEs) were extracted and pooled using Review Manager Version 5.3.Results: Data from nine selected studies were extracted. Meta-analysis of the included studies showed that HIF stabilizers reduced ferritin and hepcidin levels and increased Hb level and TIBC in NDD-CKD patients. However, HIF stabilizers only increased TIBC, and did not affect ferritin, hepcidin, and Hb levels in DD-CKD patients. Furthermore, no notable differences in AEs and severe AEs between NDD-CKD and DD-CKD patients were detected.Conclusion: HIF stabilizers are effective for the treatment of anemia in NDD-CKD patients and safe for short-term use. Keywords: hypoxia-inducible factor stabilizer, anemia, chronic kidney disease, meta-analysis

Published
2018

39. RETRACTED ARTICLE: Matrine suppresses the migration and invasion of NSCLC cells by inhibiting PAX2-induced epithelial-mesenchymal transition

Author

Yang,Jun, He,Du, Peng,Yan, Zhong,Hongzhen, Deng,Yuhong, Yu,Zhonghua, Guan,Chengnong, Zuo,Yufang, Xu,Zumin, Yang,Jun, He,Du, Peng,Yan, Zhong,Hongzhen, Deng,Yuhong, Yu,Zhonghua, Guan,Chengnong, Zuo,Yufang, and Xu,Zumin

Abstract

This paper has been retracted. Yang J, He D, Peng Y, et al. OncoTargets and Therapy. 2017;10:5209–5217. The Editor and Publisher of OncoTargets and Therapy wish to retract the published article. Following the authors request to make corrections an investigation found several images within Figures 2 and 5 appeared to have been duplicated. Figure 2A, A549, Migration, (0mg/mL), appears to have been duplicated with the same images for Figure 2A, A549, Migration, (0.5mg/mL); Invasion (0mg/mL); Invasion, (0.5mg/mL) and Figure 2B, H1299, Invasion, (0mg/mL). Figure 2A, A549, Migration, (1mg/mL), appears to have been duplicated with the same images for Figure 2A, A549, Invasion, (1mg/mL) and Figure 2B, H1299, Migration, (1mg/mL). Figure 5C, A459, GAPDH, appears to have been duplicated with the same image for Figure 5D, H1299, GAPDH. The authors cooperated with the investigation and provided data associated with the study. However, despite the authors’ assistance, they were unable to provide a satisfactory explanation for how the images came to be duplicated, and the validity of the published work could not be verified. The decision was made to retract the article and the authors agreed with this. We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Published
2017

41. The Expression and Molecular Mechanisms of Matrix Metalloproteinase- 9 and Vascular Endothelial Growth Factor in Renal Interstitial Fibrosis in Rats.

Author

Lin S, Lin W, Zhong Z, Zhong H, Zhou T, and Weng W

Subjects
Animals, Male, Rats, Kidney metabolism, Kidney pathology, Kidney Diseases metabolism, Kidney Diseases pathology, Kidney Diseases etiology, Transforming Growth Factor beta1 metabolism, Transforming Growth Factor beta1 genetics, Fibronectins metabolism, Ureteral Obstruction metabolism, Ureteral Obstruction pathology, Collagen Type IV metabolism, Disease Models, Animal, Matrix Metalloproteinase 9 metabolism, Matrix Metalloproteinase 9 genetics, Vascular Endothelial Growth Factor A metabolism, Vascular Endothelial Growth Factor A genetics, Fibrosis metabolism, Rats, Sprague-Dawley
Abstract

Objective: To explore a new approach for the treatment of renal interstitial fibrosis (RIF), we detected the expression of matrix metalloproteinase-9 (MMP9) and vascular endothelial growth factor (VEGF)., Methods: Twenty-four male Sprague Dawley (SD) rats were randomly divided into 2- week normal control (2NC) group, 4-week NC (4NC) group, 2-week unilateral ureteral obstruction (2UUO) group, and 4-week UUO (4UUO) group. We performed left ureteral ligation on UUO groups. Then, we sacrificed the rats of the 2NC group and 2UUO group at 2 weeks and the other groups at 4 weeks after the surgery. Immunohistochemistry and western blot were applied to detect the expression of MMP9, VEGF, fibronectin (FN), type IV collagen (Col-IV), and transforming growth factor-β1 (TGF-β1). MMP9 levels reduced after UUO surgery. Its expression was less in the 4UUO group than in the 2UUO group (P<0.05). The expression of VEGF, TGF- β1, FN, and Col-IV was higher in UUO groups than in NC groups (P<0.05). The expression of these indicators was higher in the 4UUO group than in the 2UUO group (P<0.05)., Results: In the correlation analysis, MMP9 levels in UUO groups had a negative correlation with the expression of TGF-β1, VEGF, Col-IV, FN, and RIF index (all P<0.05). In UUO groups, VEGF levels had a positive correlation with the expression of TGF-β1, Col-IV, FN, and RIF index (all P<0.05)., Conclusion: In conclusion, with the aggravation of RIF lesions, MMP9 levels decreased, and VEGF levels increased. Whether there is a mutual inhibition relationship between them remains to be confirmed by further experiments., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)

Published
2024
Full Text
View/download PDF

42. [Synergistic Antitumor Effect of Amorphigenin Combined with Cisplatin in Human Lung Adenocarcinoma A549/DDP Cells].

Author

Zhong H, Zuo Y, Wu X, Peng Y, He H, Yang J, Guan C, and Xu Z

Subjects
A549 Cells, Adenocarcinoma genetics, Adenocarcinoma metabolism, Adenocarcinoma physiopathology, Adenocarcinoma of Lung, Apoptosis drug effects, Caspase 3 genetics, Caspase 3 metabolism, Cell Proliferation drug effects, Drug Synergism, Humans, Lung Neoplasms genetics, Lung Neoplasms metabolism, Lung Neoplasms physiopathology, Poly(ADP-ribose) Polymerases genetics, Poly(ADP-ribose) Polymerases metabolism, Rotenone pharmacology, Adenocarcinoma drug therapy, Antineoplastic Agents pharmacology, Cisplatin pharmacology, Lung Neoplasms drug therapy, Plant Extracts pharmacology, Rotenone analogs & derivatives
Abstract

Background: Amorphigenin, a rotenoid compouns, from seeds of Amorpha fruticosa, has been shown to possess anti-proliferation activities in several cancer cells. To explore the antitumor effects of amorphigenin on cisplatin-resistant human lung adenocarcinoma A549/DDP cells and explore the underlying mechanisms., Methods: CCK-8 assay was used to measure the proliferation of A549/DDP cells; Colony formation assay was used to measure the colony formation of A549/DDP cells; Flow cytometry assay was used to detect the apoptosis rates; Western blot analysis was used to explore the expression of apoptosis-related proteins (caspase-3 protein, PARP protein) and lung resistance protein (LRP)., Results: Our results demonstrated that amorphigenin could inhibit the proliferation of A549/DDP cells with a inhibition concentration of 50% cell growth (IC50) at 48 h of (2.19±0.92) μmol/L. Amorphigenin could inhibit the colony formation ability and induce apoptosis of A549/DDP cells; Furthermore, amorphigenin combined with cisplatin showed synergistic proliferation-inhibitory effect and apoptosis-promoting effect in A549/DDP cells; reduced the expression of LRP of A549/DDP cells., Conclusions: Amorphigenin remarkably inhibits the proliferation and induces apoptosis in A549/DDP cells. Combination of amorphigenin with cisplatin had the synergistic inhibitory effect on A549/DDP cells by downregulating the expression of LRP.
.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results